These are approved for the coarse of action of chronic hepatitis B around adults sustaining grounds to believe of active viral replication & either grounds to believe of lasting elevations within blood serum aminotransferases (ALT or even AST) or histologically active disease. These are the failing coarse of action for HIV.

Adefovir was developed & is marketed by Gilead Sciences with the brand Hepsera. It was originally developed for HIV with the brand Preveon, however a U.S. Food and Drug Administration (FDA) refused to approve adefovir as a treatment for even HIV around November 1999 due to the severity and frequency of kidney toxicity while dosed at Sixty or 120mg. Notwithstanding, lawsuits keep close at h& noticed a 10mg dose of adefovir to become an effectual and safe coarse of action for HBV. Adefovir became an sanctioned coarse of action for HBV around the United States within September 2002 & in the European Union in March 2003.

A NtRTI class of antiretroviral drugs also includes a anti-HIV drug tenofovir (Viread), also developed by Gilead Sciences.